Aptose Biosciences (NASDAQ:APTO) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Friday, Benzinga reports. The brokerage currently has a $7.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Aptose Biosciences’ Q2 2024 earnings at ($0.58) EPS, Q3 2024 earnings at ($0.64) EPS, Q4 2024 earnings at ($0.69) EPS and FY2024 earnings at ($2.62) EPS.

Other equities research analysts also recently issued reports about the company. StockNews.com started coverage on Aptose Biosciences in a research note on Friday. They set a hold rating for the company. Piper Sandler reaffirmed an overweight rating and set a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group decreased their target price on shares of Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a research report on Thursday, May 16th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $14.83.

Aptose Biosciences Stock Down 1.8 %

APTO stock opened at $0.87 on Friday. The company has a 50 day moving average of $1.15 and a two-hundred day moving average of $1.71. The company has a market cap of $15.81 million, a price-to-earnings ratio of -0.14 and a beta of 1.39. Aptose Biosciences has a 12-month low of $0.85 and a 12-month high of $5.86.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.09. On average, research analysts anticipate that Aptose Biosciences will post -2.67 EPS for the current year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC lifted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 40.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 74,666 shares of the biotechnology company’s stock after buying an additional 21,334 shares during the quarter. Annandale Capital LLC owned about 0.99% of Aptose Biosciences worth $209,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.